In this randomized clinical trial that included 162 children aged 6 months to 5 years with moderate-to-severe AD, total infections were not significantly different between the dupilumab and placebo groups.

Rates of adjudicated non-herpetic skin infections and bacterial infections and the number of patients using anti-infective medications were significantly lower in the dupilumab group.

Overall safety was consistent with the known safety profile of dupilumab.